Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33653616)
Watch
English
Chemotherapy for hormone refractory prostate cancer.
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
review article
1 reference
stated in
Europe PubMed Central
title
Chemotherapy for hormone refractory prostate cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
main subject
chemotherapy
1 reference
based on heuristic
inferred from title
prostate cancer
1 reference
based on heuristic
inferred from title
author
David C. Smith
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
author name string
Smith DC
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
retrieved
28 July 2017
publication date
1 May 1999
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
published in
Urologic Clinics of North America
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
volume
26
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
issue
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
page(s)
323-331
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
cites work
Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanisms of action and clinical uses of estramustine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral estramustine and oral etoposide for hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Suramin, an active drug for prostate cancer: interim observations in a phase I trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nuclear protein matrix as a target for estramustine-induced cell death
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of topotecan in metastatic hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral etoposide in the treatment of hormone-refractory prostate cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral cyclophosphamide for the management of hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Development and validation of a pharmacokinetically based fixed dosing scheme for suramin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy Programs of the National Prostatic Cancer Project (NPCP)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy of Advanced Prostatic Carcinoma with Cyclophosphamide or 5-Fluorouracil: Results of First National Randomized Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Supercoiled loops and eucaryotic DNA replicaton
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970072-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0094-0143(05)70072-0
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
PubMed publication ID
10361555
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10361555
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10361555%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit